Late last year, EssilorLuxottica announced the U.S. Food and Drug Administration (FDA) had granted market authorization for its Essilor® Stellest® lens using the De Novo pathway. This follows the product’s earlier recognition with the FDA granting designation as a Breakthrough Technology in 2021. The The effectiveness of the Essilor Stellest lens is evidenced by clinical data showing that it slowed down myopia progression by 71% on average over a two-year period.
U.S. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia. Sept 2025.
The sharp rise in myopia is a growing concern in India, with nearly 50% of urban children projected to be affected by 2050. With its legacy of clinical reliability, EssilorLuxottica aims to advance myopia care in India through FDA-approved innovations for slowing down of Myopia progression aligned with National Accreditation Board for Hospitals (NABH) & Healthcare Providers and global standards. By empowering doctors, parents, and institutions with internationally recognized, evidence-based myopia management, the goal is to transform the standard of care by making Essilor® Stellest® accessible to more children across India.
As eye testing is not mandatory in India there are many children that go undetected or uncorrected and it’s important for parents to include eye testing as part of their routine back to school checks. Myopia is not just a refractive error; it’s a disease which can progress – standard lenses can only correct myopia they cannot control its progression. It’s important therefore for parents to check yearly so that the child can see clearly.
EssilorLuxottica is prioritizing regions with high myopia awareness and early adoption potential, including Metro cities and emerging hubs like Pune, Coimbatore, Ahmedabad, Kochi, and Chandigarh. The expansion will gradually extend to Tier-2 and Tier-3 cities through optical ophthalmologists, optometrists, and optical networks and professional education programs.
